89,581 Shares in CeriBell, Inc. $CBLL Acquired by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in CeriBell, Inc. (NASDAQ:CBLL) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 89,581 shares of the company’s stock, valued at approximately $1,742,000.

Several other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in shares of CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares during the last quarter. Rhumbline Advisers raised its position in CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after buying an additional 17,177 shares during the last quarter. New York State Common Retirement Fund raised its position in CeriBell by 148.6% in the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the last quarter. Quantbot Technologies LP lifted its stake in CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after acquiring an additional 6,401 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of CeriBell during the 2nd quarter valued at about $197,000.

CeriBell Price Performance

Shares of CeriBell stock opened at $23.73 on Friday. The stock has a market cap of $910.76 million, a P/E ratio of -13.48 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The stock’s fifty day moving average is $20.11 and its 200 day moving average is $19.35. CeriBell, Inc. has a one year low of $10.85 and a one year high of $25.33.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Sell-side analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group raised their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. BTIG Research lifted their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

Insider Buying and Selling

In other CeriBell news, CFO Scott Blumberg sold 1,521 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $36,534.42. Following the sale, the chief financial officer owned 146,600 shares in the company, valued at approximately $3,521,332. This trade represents a 1.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Xingjuan Chao sold 6,068 shares of CeriBell stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $145,753.36. Following the transaction, the chief executive officer directly owned 781,731 shares in the company, valued at $18,777,178.62. This represents a 0.77% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 382,067 shares of company stock worth $8,025,866 in the last ninety days. Corporate insiders own 17.70% of the company’s stock.

CeriBell Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.